Perfil clínico del paciente con covid-19 grave en un hospital del noreste de México

Itxel Del Carmen Perez Cruz; Ramon Alejandro Martínez Hernández; Ricardo  González Pérez; Jesús Adrián Maldonado Mancillas Maldonado Mancillas

doi:10.19136/hs.a24n1.5917

Authors

Itxel Del Carmen Pérez Cruz Pasante del Servicio Social de Medicina https://orcid.org/0009-0004-8119-2071
Ramon Alejandro Martínez Hernández Adscrito al servicio de hematologia del hospital regional de alta especialidad de ciudad victoria, tamaulipas. https://orcid.org/0009-0001-6322-6838
Ricardo González Pérez Hospital General Dr. Alfredo Pumarejo Lafaurie. https://orcid.org/0009-0004-2843-7607
Jesús Adrián Maldonado Mancillas Maldonado Mancillas Hospital General Dr. Alfredo Pumarejo Lafaurie. https://orcid.org/0000-0002-2184-0004

DOI:

https://doi.org/10.19136/hs.a24n1.5917

Abstract

Objective: To determine the type of clinical profile and the association of severity of patients who developed severe COVID-19.

Materials and methods: In the general hospital of the city of Heroica, Matamoros, in the State of Tamaulipas of the United Mexican States; A collection of clinical records will be carried out to see which patients previously had medication and influenced mortality in patients with COVID 19. Through a retrospective, observational and cross-sectional study using the statistical analysis technique; using the SPSS 32 program for information processing. Taking into account the criteria for inclusion, exclusion and definitive elimination.

Results: At the Matamoros General Hospital; of 478 who suffered from severe COVID 19. A total of 161 patients were discharged due to clinical improvement compared to 317 who were taking some medication due to chronic degenerative. Of the 96 patients who did not consume medications, it was observed that 34 (6.9%) were discharged due to improvement against 63 (13.17%) who died despite not consuming medications. The combination of diabetes mellitus and hypertension resulted in 124 (25.94%) patients and 36 (7.53%) improved, against 88 (18.41%) deaths.

Conclusions: Based on the present work, we found that polypharmacy (3 or more medications), together with comorbidities; may affect the concomitant administration of the baseline treatment of COVID-19 disease and have an unfavorable outcome. In this study, he also recorded a similar percentage of deaths of patients with two or more diseases, compared to healthy patients.

Keywords: Profile; Polypharmacy; Comorbidity; Age; COVID 19.